Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchitis Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transplacental Transmission of RSV (TTRSV)

NCT05443607
View directory record Official record
Conditions
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Early Phase 1 Interventional

Iraq- Afghanistan War Lung Injury Using 19F MRI (DIAL1001006)

NCT03237364
View directory record Official record
Conditions
Constrictive Bronchiolitis, Iraq-Afganistan War Lung Injury Syndrome
Interventions
Perfluorinated Gas/Oxygen Mixture
Diagnostic Test
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

NCT00103701
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 24, 2026, 5:45 PM EDT
Terminated Phase 1 Interventional

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

NCT06695507
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 24, 2026, 5:45 PM EDT
Completed No phase listed Observational

A Study of Factors That Affect Long-Term Kidney Transplant Function

NCT00270712
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
3,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

NCT05873907
View directory record Official record
Conditions
Chronic Graft-versus-host Disease (cGVHD)
Interventions
AMG 592, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 24, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional

A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain

NCT07214844
View directory record Official record
Conditions
Low Back Pain, Chronic
Interventions
Iovera Medial Branch Cryoneurolysis, Radiofrequency ablation (RFA)
Device · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD

NCT02099799
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis
Interventions
Pedometer and Website
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 24, 2026, 5:45 PM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional

Yoga for Treating Shortness of Breath in Chronic Obstructive Pulmonary Disease (COPD)

NCT00051792
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
yoga
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

NCT02639247
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Not applicable Interventional

The ROUTT-B (Reduce Over-Utilized Tests and Treatments in Bronchiolitis) Study

NCT04302207
View directory record Official record
Conditions
Bronchiolitis
Interventions
De-implementation Strategy for Bronchiolitis
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 80 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Columbus, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome

NCT01287078
View directory record Official record
Conditions
Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Phase 2 Study - Erdosteine in Patients With CB/COPD

NCT00338507
View directory record Official record
Conditions
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
Interventions
Erdosteine
Drug
Lead sponsor
Adams Respiratory Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 24, 2026, 5:45 PM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 24, 2026, 5:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular and Fibrosis Imaging Study

NCT01758250
View directory record Official record
Conditions
Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions
Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial

NCT03277378
View directory record Official record
Conditions
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Interventions
lead placement followed by BurstDR stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Santa Rosa, California • Clearwater, Florida • Merritt Island, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD

NCT00035828
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
ABX-IL8
Drug
Lead sponsor
Abgenix
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis

NCT01107457
View directory record Official record
Conditions
Psoriasis
Interventions
Ixekizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
31
States / cities
Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 24, 2026, 5:45 PM EDT
Withdrawn Not applicable Interventional

Steroids Helping Albuterol Responders Exclusively

NCT00798616
View directory record Official record
Conditions
Bronchiolitis
Interventions
prednisolone or methylprednisolone, placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Weeks to 24 Months
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial

NCT04069312
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Interventions
Roflumilast, Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 24, 2026, 5:45 PM EDT
Recruiting Phase 1 Interventional

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

NCT07127926
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 24, 2026, 5:45 PM EDT